Efficacy and Safety of Direct Oral Anticoagulants in Stable Coronary Artery Disease and Atrial Fibrillation: A Systematic Review and Network Meta-Analysis

Direct Oral Anticoagulants (DOACs) , which partially replace warfarin, have been developed as a safe and effective therapy for patients with stable coronary artery disease (SCAD) and atrial fibrillation (AF). However, the choice of DOACs and warfarin remains controversial. We conducted a network met...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and applied thrombosis/hemostasis 2022, Vol.28, p.10760296221131033
Main Authors: Ma, Fang, Yuan, Li, Wen, Xinli, Wang, Yangyang, Li, Qiaofei, Chen, Chu
Format: Article
Language:English
Subjects:
Administration, Oral
Anticoagulants
Anticoagulants - adverse effects
Atrial Fibrillation - complications
Atrial Fibrillation - drug therapy
Cardiac arrhythmia
Cardiovascular disease
Coronary Artery Disease - complications
Coronary Artery Disease - drug therapy
Coronary vessels
Embolism - drug therapy
Embolism - etiology
Embolism - prevention & control
Embolisms
Hemorrhage - chemically induced
Hemorrhage - drug therapy
Humans
Meta-analysis
Mortality
Network Meta-Analysis
Original Manuscript
Rivaroxaban - therapeutic use
Stroke - prevention & control
Vein & artery diseases
Warfarin - adverse effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Direct Oral Anticoagulants (DOACs) , which partially replace warfarin, have been developed as a safe and effective therapy for patients with stable coronary artery disease (SCAD) and atrial fibrillation (AF). However, the choice of DOACs and warfarin remains controversial. We conducted a network meta-analysis (NMA) using randomized controlled trials (RCTs) through a systematic literature review to evaluate the the efficacy and safety of DOACs in SCAD and AF patients. Five RCTs with 6524 patients were included. The results showed that patients taking DOACs had a lower risk of stroke/systemic embolism (OR, 0.64; 95% CI, 0.54-0.76, P 
ISSN:1076-0296
1938-2723
DOI:10.1177/10760296221131033